Primary AML blasts showed a heterogenous glucose consumption, while basal glycolysis, the glycolytic reserve and the glycolytic capacity were higher with respect to NBM but comparable to values measured in early progenitors/precursors (EP/Ps) from the CB CD34+ cells at day 13 of culture (N13, mostly granulocytic differentiated cells: CD11b 72%, CD15 80% and CD34 7%) (Figure 1a and Table 2). The gene discussed is CD34; the disease is acute myeloid leukemia.